| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1995;91:2882-2890.)
© 1995 American Heart Association, Inc.
Articles |
Bleeding Complications With the Chimeric Antibody to Platelet Glycoprotein IIb/IIIa Integrin in Patients Undergoing Percutaneous Coronary Intervention
From the St Louis (Mo) University Health Sciences Center (F.V.A., T.J.D.); Cleveland Clinic (Ohio) (E.J.T.); Texas Heart Institute, Houston (J.J.F.); Centocor, Inc, Malvern, Pa (K.A., H.F.W.); Geisinger Medical Center, Danville, Pa (J.C.B.); Arizona Heart Institute and Foundation, Phoenix (R.R.H.); Duke University Medical Center, Durham, NC (K.S., R.M.C.); Deborah Heart Center, Brown Mill, NJ (M.T.); Graduate Hospital, Philadelphia, Pa (R.G.); North Memorial Medical Center, Robbinsdale, Minn (G.H.); and Lutheran General Hospital, Park Ridge, Ill (M.R.).
Correspondence to Frank V. Aguirre, MD, Division of Cardiology, St Louis University Health Sciences Center, 3635 Vista Ave at Grand Blvd, St Louis, MO 63110.
Background The potential for novel antiplatelet and antithrombin agents to contribute to periprocedural bleeding complications of percutaneous coronary revascularization is poorly defined. In the Evaluation of c7E3 Fab in Preventing Ischemic Complications of High-Risk Angioplasty (EPIC) trial, the periprocedural use of aspirin, heparin, and a chimeric antibody to the platelet glycoprotein IIb/IIIa integrin c7E3 Fab in 2099 patients significantly reduced postprocedural ischemic complications and 6-month clinical restenosis but was associated with increased procedural bleeding complications. We review these complications and describe clinical and procedural variables associated with increased bleeding complications in the EPIC trial.
Methods and Results Patients with high-risk clinical or lesion morphological characteristics were randomized to receive placebo bolus plus placebo infusion, c7E3 Fab bolus plus placebo infusion, or c7E3 Fab bolus plus c7E3 Fab infusion. Patients received periprocedural aspirin and intravenous heparin continued for a minimum of 12 hours after the procedure. Outcomes reflecting bleeding complications were measured: transfusions, decreased hemoglobin, and an index including both parameters. Major bleeding complications unrelated to bypass surgery occurred in 3.3%, 8.6%, and 10.6%, and blood product transfusions were used in 7.5%, 14.0%, and 16.8% of patients treated with placebo, bolus c7E3 Fab, and bolus plus infusion c7E3 Fab, respectively (both P<.001). Most major bleeding complications occurred at the femoral access site, regardless of treatment. Intracranial hemorrhage (0.3%) and death (0.09%) attributable to major bleeding complications were rare. Multivariable regression analyses identified several variables significantly and independently related to major bleeding complications or greater blood loss, including greater age, female sex, lower weight, c7E3 Fab therapy, and duration and complexity of the index procedure. Major bleeding complications and blood loss in patients receiving bolus plus infusion were not significantly greater than in those receiving bolus alone (P=.38 and P=.14, respectively).
Conclusions Bleeding complications unrelated to bypass surgery were two to three times more frequent in patients receiving c7E3 Fab than in those receiving placebo, but most were transient and well tolerated. Risk-factor analysis and modification of concomitant antithrombotic and antiplatelet treatment strategies may aid in reducing bleeding complications and enhancing clinical benefit in patients receiving c7E3 Fab during percutaneous coronary revascularization.
Key Words: angioplasty • platelet aggregation inhibitors • clinical trials • catheterization
This article has been cited by other articles:
 |
|
 |
|
  A. Ali, M. Hashem, H. S. Rosman, L. Moser, A. Rehan, T. Davis, M. Romanelli, T. LaLonde, H. Yamasaki, B. Barbish, et al. Glycoprotein IIb/IIIa Receptor Antagonists and Risk of Bleeding: A Single-Center Experience in 1020 Patients J. Clin. Pharmacol., November 1, 2004; 44(11): 1328 - 1332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J.G. Peters, S. R. Mehta, K. A.A. Fox, F. Zhao, B. S. Lewis, S. L. Kopecky, R. Diaz, P. J. Commerford, V. Valentin, S. Yusuf, et al. Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes: Observations From the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Circulation, October 7, 2003; 108(14): 1682 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Willerson Myocardial Revascularization with Cardiologic Interventional Devices Card. Surg. Adult, January 1, 2003; 2(2003): 561 - 580. [Full Text]
|
|
|
|
 |
|
 R. Chun, B. A. Orser, and M. Madan Platelet Glycoprotein IIb/IIIa Inhibitors: Overview and Implications for the Anesthesiologist Anesth. Analg., October 1, 2002; 95(4): 879 - 888. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Y Lee, W. DeBois, K. H Krieger, L. N Girardi, L. Russo, J. McVey, W. Ko, N. K Altorki, R. A Brodman, and O W. Isom The effects of platelet inhibitors on blood use in cardiac surgery Perfusion, January 1, 2002; 17(1): 33 - 37. [Abstract] [PDF]
|
|
|
|
|
|
H. V. Anderson, J. McNatt, F. J. Clubb, M. Herman, J.-P. Maffrand, F. DeClerck, C. Ahn, L. M. Buja, and J. T. Willerson Platelet Inhibition Reduces Cyclic Flow Variations and Neointimal Proliferation in Normal and Hypercholesterolemic-Atherosclerotic Canine Coronary Arteries Circulation, November 6, 2001; 104(19): 2331 - 2337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Despotis, M. S. Avidan, and C. W. Hogue Jr Mechanisms and attenuation of hemostatic activation during extracorporeal circulation Ann. Thorac. Surg., November 1, 2001; 72(5): S1821 - 1831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Smith Jr, J. T. Dove, A. K. Jacobs, J. Ward Kennedy, D. Kereiakes, M. J. Kern, R. E. Kuntz, J. J. Popma, H. V. Schaff, D. O. Williams, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions J. Am. Coll. Cardiol., June 15, 2001; 37(8): 2239 - 2239. [Full Text] [PDF]
|
|
|
|
|
|
C. S. Roberts and N. R. Bocanegra Emergent operation for percutaneous coronary rupture after abciximab administration Ann. Thorac. Surg., June 1, 2001; 71(6): 2024 - 2026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Chew and D. J. Moliterno A critical appraisal of platelet glycoprotein IIb/IIIa inhibition J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2028 - 2035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Lincoff, L. A. LeNarz, G. J. Despotis, P. K. Smith, J. E. Booth, R. E. Raymond, S. K. Sapp, C. F. Cabot, J. E. Tcheng, R. M. Califf, et al. Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials Ann. Thorac. Surg., August 1, 2000; 70(2): 516 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Silvestry and P. K. Smith Current status of cardiac surgery in the abciximab-treated patient Ann. Thorac. Surg., August 1, 2000; 70(2): S12 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Lemmer Jr Clinical experience in coronary bypass surgery for abciximab-treated patients Ann. Thorac. Surg., August 1, 2000; 70(2): S33 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Cauwenberghs, M. Meiring, S. Vauterin, V. van Wyk, S. Lamprecht, J. P. Roodt, L. Novak, J. Harsfalvi, H. Deckmyn, and H. F. Kotze Antithrombotic Effect of Platelet Glycoprotein Ib-Blocking Monoclonal Antibody Fab Fragments in Nonhuman Primates Arterioscler. Thromb. Vasc. Biol., May 1, 2000; 20(5): 1347 - 1353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Weiss, M. L. Mirsky, O. A. Evanson, J. Fagliari, D. Mcclenahan, and B. Mccullough Platelet Kinetics in Dogs Treated with a Glycoprotein IIb/IIIa Peptide Antagonist Toxicol Pathol, March 1, 2000; 28(2): 310 - 316. [Abstract] [PDF]
|
|
|
|
|
|
J. H. Lemmer Jr, M. T. Metzdorff, A. H. Krause Jr, M. A. Martin, J. E. Okies, and J. G. Hill Emergency coronary artery bypass graft surgery in abciximab-treated patients Ann. Thorac. Surg., January 1, 2000; 69(1): 90 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rabah, D. Mason, D. W. M. Muller, R. Hundley, A. D. Kugelmass, B. Weiner, L. Cannon, W. W. O'Neill, and R. D. Safian Heparin after percutaneous intervention (HAPI): a prospective multicenter randomized trial of three heparin regimens after successful coronary intervention J. Am. Coll. Cardiol., August 1, 1999; 34(2): 461 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nishida, H. Ueno, N. Atsuchi, R. Kawano, Y. Asada, Y. Nakahara, Y.-i. Kamikubo, A. Takeshita, and H. Yasui Adenovirus-Mediated Local Expression of Human Tissue Factor Pathway Inhibitor Eliminates Shear Stress–Induced Recurrent Thrombosis in the Injured Carotid Artery of the Rabbit Circ. Res., June 25, 1999; 84(12): 1446 - 1452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Vorchheimer, J. J. Badimon, and V. Fuster Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Cardiovascular Disease JAMA, April 21, 1999; 281(15): 1407 - 1414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Duda, J. Wiskirchen, M. Erb, U. Schott, K. Khaligi, P. L. Pereira, J. Albes, and C. D. Claussen Suture-mediated Percutaneous Closure of Antegrade Femoral Arterial Access Sites in Patients Who Have Full Anticoagulation Therapy Radiology, January 1, 1999; 210(1): 47 - 52. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. Khanlou, G. Eiger, S. Yazdanfar, S. A. Cohen, and M. B. Effron Abciximab and Alveolar Hemorrhage N. Engl. J. Med., December 17, 1998; 339(25): 1861 - 1863. [Full Text]
|
|
|
|
 |
|
 K. Peter, M. Schwarz, J. Ylanne, B. Kohler, M. Moser, T. Nordt, P. Salbach, W. Kubler, and C. Bode Induction of Fibrinogen Binding and Platelet Aggregation as a Potential Intrinsic Property of Various Glycoprotein IIb/IIIa (alpha IIbbeta 3) Inhibitors Blood, November 1, 1998; 92(9): 3240 - 3249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Breddin Antiplatelet Agents in Cardiovascular and Cerebrovascular Diseases Clinical and Applied Thrombosis/Hemostasis, April 1, 1998; 4(2): 87 - 95. [Abstract] [PDF]
|
|
|
|
|
|
J. S. Gammie, M. Zenati, R. L. Kormos, B. G. Hattler, L. M. Wei, R. V. Pellegrini, B. P. Griffith, and C. M. Dyke Abciximab and Excessive Bleeding in Patients Undergoing Emergency Cardiac Operations Ann. Thorac. Surg., February 1, 1998; 65(2): 465 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. V. Anderson, R. E. Jordan, and H. F. Weisman Concept and Clinical Application of Platelet Glycoprotein IIb/IIIa Inhibition with Abciximab (c7E3 Fab; ReoPro) for the Prevention of Acute Ischemic Syndromes Clinical and Applied Thrombosis/Hemostasis, October 1, 1997; 3(4): 256 - 266. [Abstract] [PDF]
|
|
|
|
|
|
C. Simpfendorfer, K. Kottke-Marchant, M. Lowrie, R. J. Anders, D. M. Burns, D. P. Miller, C. S. Cove, A. C. DeFranco, S. G. Ellis, D. J. Moliterno, et al. First Chronic Platelet Glycoprotein IIb/IIIa Integrin Blockade : A Randomized, Placebo-Controlled Pilot Study of Xemilofiban in Unstable Angina With Percutaneous Coronary Interventions Circulation, July 1, 1997; 96(1): 76 - 81. [Abstract] [Full Text]
|
|
|
|
|
|
The EPILOG Investigators Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularization N. Engl. J. Med., June 12, 1997; 336(24): 1689 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Aggarwal, D. C. Ireland, M. A. Azrin, M. D. Ezekowitz, D. P. de Bono, and A. H. Gershlick Antithrombotic Potential of Polymer-Coated Stents Eluting Platelet Glycoprotein IIb/IIIa Receptor Antibody Circulation, December 15, 1996; 94(12): 3311 - 3317. [Abstract] [Full Text]
|
|
|
|
|
|
L. Oltrona, P. R. Eisenberg, J. M. Lasala, D. J. Sewall, M. E. Shelton, and K. J. Winters Association of Heparin-Resistant Thrombin Activity With Acute Ischemic Complications of Coronary Interventions Circulation, November 1, 1996; 94(9): 2064 - 2071. [Abstract] [Full Text]
|
|
|
|
|
|
P. Theroux, S. Kouz, L. Roy, M. L. Knudtson, J. G. Diodati, J.-F. Marquis, J. Nasmith, A. Y. Fung, J.-R. Boudreault, F. Delage, et al. Platelet Membrane Receptor Glycoprotein IIb/IIIa Antagonism in Unstable Angina: The Canadian Lamifiban Study Circulation, September 1, 1996; 94(5): 899 - 905. [Abstract] [Full Text]
|
|
|
|
|
|
D. B. Mark, J. D. Talley, E. J. Topol, L. Bowman, L. C. Lam, K. M. Anderson, J. G. Jollis, M. W. Cleman, K. L. Lee, T. Aversano, et al. Economic Assessment of Platelet Glycoprotein IIb/IIIa Inhibition for Prevention of Ischemic Complications of High-Risk Coronary Angioplasty Circulation, August 15, 1996; 94(4): 629 - 635. [Abstract] [Full Text]
|
|